Akthelia Pharmaceuticals is featured in today's edition of the leading Icelandic business newspaper Viðskiptablaðið.

Akthelia Pharmaceuticals is pleased to announce it has been awarded a two-year $350,000 research grant by RANNIS

Akthelia Pharma will present exciting new translational data, and partnering and capital raising objectives at Nordic Life Science Days 2024

Akthelia Pharmaceuticals announce its award of the European Commission Seal of Excellence, a quality recognition by the European Union.

Akthelia Pharmaceuticals is at a pivotal juncture, with a strongly validated and developable lead asset, ready to enter IND-enabling studies

Dr Sonja Srdanović joins Akthelia Pharma as R&D Program Manager for Inflammation and Infection

Akthelia Pharmaceuticals will attend the Nordic Life Science Days Summit in Copenhagen, 9 - 30 November 2023 REYKJAVIK, Iceland -- 30...

Helga Kristín Einarsdóttir joins Akthelia as R&D Program Manager for Wound Therapeutics.

Akthelia Pharmaceuticals and the University of Iceland Secure a €6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)

Akthelia Pharma selected to present at the Science4Peace Summit in Stockholm, Dec 2022

Akthelia Pharmaceuticals Participates in the LSX Leaders Nordic Congress 2022

Akthelia Pharmaceuticals Announces Second Close of Follow-Up Pre-Seed Equity Round

Akthelia Pharma Announce Close of Follow-Up Pre-Seed Equity Round

Highly experienced research scientist Dr Steingrímur Stefánsson joins Akthelia to boost R&D capabilities

RANNÍS, the Icelandic technology fund, has awarded Akthelia Pharma $330,000 for the initial development of its novel wound healing approach.

Akthelia Pharma Announces Close of a Pre-Seed Equity Round

RANNÍS, the Icelandic technology fund, has awarded Akthelia Pharma $330,000 to develop a proof of concept

Akthelia will attend the 2019 ANTIMICROBIAL PEPTIDES GORDON RESEARCH CONFERENCE